Additionally, the combination of MLN0128 (PI3K/AKT inhibitor), along with trametinib (MEK1/2 inhibitor), activated an interaction between PI3K/mTOR and MAPK/ERK, exhibiting synergistic effects in MCC cell lines, indicating a promising synergistic strategy [57]. This evidence concerns the gene PIK3CA and Merkel cell skin cancer.